Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abreva enters new markets

This article was originally published in The Tan Sheet

Executive Summary

Cold sore remedy approved for OTC sale in Canada, could be available by year end under exclusive licensing agreement with GlaxoSmithKline, Avanir Pharmaceuticals says May 28. Deal with GSK, which was announced in March 2000 and also gave GSK U.S. marketing rights to Abreva, provides Avanir with royalties based on wholesale product revenue. Before GSK launches the docosanol 10% cream in Canada, firm must attain provincial approval from the national drug scheduling recommendation committee; GSK is scheduling a presentation before committee for September. Avanir also announces product approvals in Korea, Israel...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel